Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Depreciation (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Accumulated Depreciation for 11 consecutive years, with $58.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 17.94% to $58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.6 million through Dec 2025, up 17.94% year-over-year, with the annual reading at $58.6 million for FY2025, 17.94% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $58.6 million at Intellia Therapeutics, up from $49.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $58.6 million in Q4 2025, with the low at $26.1 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $41.5 million, with a median of $39.9 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation surged 35.09% in 2021, then grew 17.94% in 2025.
  • Over 5 years, Accumulated Depreciation stood at $26.1 million in 2021, then grew by 27.13% to $33.2 million in 2022, then grew by 20.07% to $39.9 million in 2023, then grew by 24.66% to $49.7 million in 2024, then increased by 17.94% to $58.6 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $58.6 million, $49.7 million, and $39.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.